Dal Gene

Principle Investigator:
Dr Peter Wilkinson

DAL GenE is a genetics based trial looking at a specific genetic population who have suffered a heart attack who may benefit from a new drug called Dalcetrapib. This drug has shown to increase HDL “good” cholesterol levels and potentially reduces your risk of another heart attack.

Inpatients who have suffered a heart attack may be approached about the opportunity to take part in this study. This will only involve a genetic blood test to determine their eligibility prior to discharge. If they have the gene of interest then they would be eligible to be enrolled into the main 3 year study.

Clear Outcomes Study

Principle Investigator:
Dr Sumeet Sharma

Clear Outcomes study is one of 4 international trials currently assessing the effects of a new drug called Bempedoic Acid related to cardiovascular disease and its associated risks. Bempedoic acid is thought to have the same medicinal effect as statins; where they differ is how they are broken down or ‘metabolised’ in the body. When statins are metabolised in the liver, their break-down products can end up in muscle, which can lead to muscle-related side effects. Bempedoic acid’s break-down products remain in the liver and are removed from the body, therefore reducing the side effects. This study is only suitable for individuals who are statin intolerant.

ARTESiA

Principle Investigator:
Dr Mark Williams

ARTESiA is an atrial fibrillation trial looking at people who have an Implantable Cardiac Device such as a pacemaker, ICD or loop recorder, who during their pacing appointment have been identified as having one or more episodes of AF since their last visit. The study is looking to test if an anticoagulant blood thinning drug called apixaban is superior to aspirin for prevention of stroke and systemic embolism.

Patients would randomly be assigned either Apixaban OR Aspirin and will be followed up regularly alongside pacing appointments.

AEGIS-II

Principle Investigator:
Dr Sumeet Sharma

After a cardiovascular event (Heart attack/Stroke) a person’s risk of recurrent CV events is high despite advances in medical therapy and standard therapeutic regimens that have produced important improvements in the prognosis of these patients. CSL112 is a novel formulation of apoA-I, the major functional component of high-density lipoprotein (good cholesterol).

AEGIS-I demonstrated that administration of apoA-I increases cholesterol to be removed from the body in CV patients. This new trial is a randomized placebo-controlled trial where eligible patients will either be randomly assigned to being given a 2 hour apoA infusion or a placebo infusion prior to discharge from their index event and subsequently once a week for 3 weeks after. Patients are continued to be followed up for one year post-index event.

SELECT

Principle Investigator:
Dr Sumeet Sharma

People with overweight or obesity are at high risk for cardiovascular (CV) disease. Semaglutide has shown CV risk reduction and impact on CV risk factors including overweight, raised glucose levels and high blood pressure in subjects with type 2 diabetes.

The SELECT trial aims to demonstrate the effect Semaglutide has on CV risk reduction and risk factors in individuals with already established CV disease and overweight or obesity. Individuals will be randomly assigned to either 2.4mg once-weekly sub-cutaneous Semaglutide or placebo added to standard of care and followed up for a mean length of 3-4 years.

ORION-4

Principle Investigator:
Dr Peter Wilkinson

ORION-4 is a research study being coordinated by the University of Oxford and co-sponsored by The University of Oxford and The Medicines Company. The study is investigating a new medication called Inclisiran which helps to lower bad (LDL) cholesterol and aims to find out whether having an injection of Inclisiran every 6 months prevents heart attacks and strokes in individuals who have already had one of these conditions.

About 15,000 people will take part in this study across the UK. Half will get the Inclisiran injections and half will get dummy (inactive placebo) injections. Which treatment you get is randomly decided by a computer and we will not know which treatment you are given. The study is due to last approximately 5 years.

AF III Registry

Principle Investigator:
Dr Zhong Chen

This registry is open for 3 months’ to highlight the number of patients attending hospital, as an inpatient or outpatient that have atrial fibrillation. The study is comparing how patients are currently treated compared to the European ESC guidelines. This is an observational study, which means there is no change to standard clinical care and the follow up is 12 months after enrolment.

CRAFT

Principle Investigator:
Dr Zhong Chen

Cryoballoon Pulmonary Vein Isolation as first line treatment for typical atrial flutter. Patient’s with atrial flutter whom require ablation therapy will be randomized into either having conventional management by substrate removal (Cavotricuspid Isthmus (CTI) ablation) or novel management by trigger removal (no CTI ablation). Patient’s will be followed up at 3 and 12 months’ post-ablation in line with clinical care.

Prevalence Lp(a) – Prevalence of Lipoprotein a in patients with established cardiovascular disease

Principle Investigator:
Dr Sumeet Sharma

The purpose of the study is to collect information about the blood level of a type of cholesterol called Lipoprotein (a) or Lp (a). The study will also collect information about your Low Density Lipoprotein Cholesterol (LDL-C), commonly referred to as ‘bad’ cholesterol.

Lipoprotein(a) levels are found in patients with associated furring of the arteries, known as atherosclerosis, which leads to conditions such as heart attacks, stroke or peripheral artery disease (severe pain in legs while walking or lower limb amputation). In this world-wide study, we will collect information from patients with furring of arteries to better understand the role of lipoprotein (a) levels in patients at risk of heart attacks, strokes and peripheral artery disease over a wide geographical area.

Biostream-HF - Observation of clinical routine care for heart failure patients implanted with BIOTRONIK CRT devices

Principle Investigator:
Dr Zhong Chen

The purpose of the BIO|STREAM.HF study is to gain additional knowledge about outcome, efficacy and residual safety aspects of BIOTRONIK CRT based on long-term data from a general patient population in routine care. The monitoring of these patients may help to find possible predictors for heart failure events and to identify areas of improvement for CRT and for CRT device settings.